Clinical Trials · NCT02531516
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Aragon Pharmaceuticals, Inc.
- Enrollment
- 1,503
- Start date
- Nov 2015
- Locations
- 263 sites, 23 countries
- Primary endpoint
- Metastasis-Free Survival (MFS)